The therapeutic decision regarding estrogen receptor-­positive (ERα+) and ERα-negative (ERα−) breast cancer (BC) patients is mainly based on the evaluation of clinicopathological characteristics. This evidence concerns the gene ESR1 and breast carcinoma.